-
Chapter and Conference Paper
Combination of 5-FU, Leucovorin and Cisplatin (CDDP): an efficient low-toxic chemotherapy in advanced gastric adenocarcinoma
Metastatic gastric cancer remains a frequent disease with spontaneous median survival of about 6 months [1]. FAM regimen (5-FU, Doxorubicin and Mitomycin) was until the nineteens, considered as standard treatm...
-
Article
Open AccessInvolvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model
Both experimental and clinical data show evidence of a correlation between elevated blood levels of carcinoembryonic antigen (CEA) and the development of liver metastases from colorectal carcinomas. However, a...
-
Article
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
Abstract
-
Article
Open AccessPotentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
The aim of this study was to treat carcinoembryonic antigen (CEA)-expressing pancreatic carcinoma cells with tumour necrosis factor alpha (TNFα) and simultaneous radiation therapy (RT), using a bispecific antibod...
-
Article
Open Accessp53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis
The aim of this study was to evaluate, in a prospective study, the predictive role of p53 status analysed at four different levels in identifying the response to preoperative radiotherapy in rectal adenocarcin...
-
Article
Le point sur la prise en charge des cancers digestifs
-
Article
Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques
Malgréde récents progrés dans la prise en charge des adénocarcinomes œsogastriques (AOG), leur mortalitéreste élevée et leur traitement est encore un véritable challenge pour les oncologues. Le traitement chir...
-
Article
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
To assess the rate of R0 resection of liver metastases achieved after chemotherapy with FOLFIRINOX.
-
Article
Open AccessPhase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in...
-
Article
Open AccessTP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based ...
-
Article
Open AccessQuality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic color...
-
Article
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals a...
-
Article
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
-
Article
Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an ...
-
Article
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of th...
-
Article
Open AccessSorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progre...
-
Article
Open AccessAntibody targeting of claudin-1 as a potential colorectal cancer therapy
Metastatic colorectal cancer (mCRC) is one of the major causes of cancer-related death. Despite the substantial progress in mCRC management, it remains important to identify new therapeutic options and biologi...
